Sonidegib治疗局部晚期和转移性基底细胞癌的长期疗效与安全性:BOLT随机2期研究30个月分析
BOLT研究为双盲2期试验,纳入不适合治愈性手术或放疗的局部晚期基底细胞癌(laBCC)或转移性基底细胞癌(mBCC)患者,随机接受sonidegib 200 mg或800 mg。30个月随访显示,200 mg组laBCC客观缓解率为56.1%(中心评估)和71.2%(研究者评估),mBCC为7.7%和23.1%;缓解持久,安全性优于800 mg。
要点
- sonidegib 200 mg在laBCC中客观缓解率中心评估56.1%、研究者评估71.2%。
- laBCC中位缓解持续时间中心评估26.1个月,研究者评估15.7个月。
- 200 mg组3/4级不良事件发生率43.0%,低于800 mg组的64.0%。
核心结论
- sonidegib 200 mg在laBCC和mBCC中持续显示长期疗效和安全性,支持按当地治疗指南使用200 mg剂量。
研究设计与样本
- BOLT为双盲2期研究(NCT01327053),2011年7月至2013年1月入组未接受过Hedgehog通路抑制剂(HPI)治疗的laBCC或mBCC患者。
- 患者随机1:2接受sonidegib 200 mg(laBCC n=66,mBCC n=13)或800 mg(laBCC n=128,mBCC n=23)。
- 肿瘤缓解由中心和研究者评估。
主要发现
- 30个月随访时,200 mg组laBCC客观缓解率中心评估56.1%、研究者评估71.2%;mBCC中心评估7.7%、研究者评估23.1%。
- 200 mg组laBCC中位缓解持续时间中心评估26.1个月、研究者评估15.7个月;mBCC中心评估24.0个月、研究者评估18.1个月。
- 200 mg组laBCC死亡5例、mBCC死亡3例;laBCC和mBCC中位总生存均未达到,2年总生存率分别为93.2%和69.3%。
- laBCC中疗效在侵袭性和非侵袭性组织学间相似。
- 200 mg组3/4级不良事件发生率43.0%,800 mg组64.0%;导致停药的不良事件发生率分别为30.4%和40.0%。
关键数值与推荐
- laBCC客观缓解率:200 mg组中心评估56.1%、研究者评估71.2%。
- mBCC客观缓解率:200 mg组中心评估7.7%、研究者评估23.1%。
- laBCC中位缓解持续时间:中心评估26.1个月、研究者评估15.7个月。
- mBCC中位缓解持续时间:中心评估24.0个月、研究者评估18.1个月。
- 2年总生存率:laBCC 93.2%,mBCC 69.3%。
临床怎么用
- 对于不适合治愈性手术或放疗的laBCC患者,sonidegib 200 mg可作为全身治疗选择。
- mBCC患者使用sonidegib 200 mg时需权衡较低的客观缓解率。
- 200 mg剂量较800 mg具有更好的安全性,支持按指南使用200 mg。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult-to-treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on results from the BOLT trial. OBJECTIVE: To evaluate long-term efficacy and safety of sonidegib in laBCC and mBCC in the BOLT 18- and 30-month analyses. METHODS: BOLT (NCT01327053, ClinicalTrials.gov), a double-blind phase 2 study, enrolled patients from July 2011 until January 2013. Eligible HPI-treatment-naïve patients with laBCC not amenable to curative surgery/radiotherapy or mBCC were randomized 1 : 2 to sonidegib 200 mg (laBCC, n = 66; mBCC, n = 13) or 800 mg (laBCC, n = 128; mBCC, n = 23). Tumour response was assessed per central and investigator review. RESULTS: With 30 months of follow-up, among patients treated with sonidegib 200 mg (approved dose), objective response rates were 56.1% (central) and 71.2% (investigator) in laBCC and 7.7% (central) and 23.1% (investigator) in mBCC. Tumour responses were durable as follows: median duration of response was 26.1 months (central) and 15.7 months (investigator) in laBCC and 24.0 months (central) and 18.1 months (investigator) in mBCC. Five patients with laBCC and three with mBCC in the 200-mg arm died. Median overall survival was not reached in either population; 2-year overall survival rates were 93.2% (laBCC) and 69.3% (mBCC). In laBCC, efficacy was similar regardless of aggressive or non-aggressive histology. Sonidegib 200 mg continued to have a better safety profile than 800 mg, with lower rates of grade 3/4 adverse events (43.0% vs. 64.0%) and adverse events leading to discontinuation (30.4% vs. 40.0%). CONCLUSION: Sonidegib continued to demonstrate long-term efficacy and safety in these populations. These data support the use of sonidegib 200 mg per local treatment guidelines.
引用
- Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2017. PMID: 28846163. doi:10.1111/jdv.14542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。